
Roche Phase III study misses COVID-19 endpoint
In the Phase III REMDACTA trial, the Swiss pharma major combined its cytokine storm blocker tocolizumab with Gilead Science’s viral transcription...

Media hype on Denmark’s decision to halt AZD1222 vaccination
Since Denmark suspended vaccination with AstraZeneca’s bashed Covid-19 vaccine, AZD1222 is facing questions over its safety. Denmark’s...

BioVersys gets €20m EIB loan to develop novel antibiotics
The venture debt loan is financed under the Infectious Diseases Finance Facility set up as part of Horizon 2020, the European Union’s research and...

EMA recommends to continue AZD1222 vaccinations
After the stops of AstraZeneca's COVID-19 vaccine or specific batches of it in 13 EU member states, the EU regulatory authority EMA has analysed the...

C4X Discovery and Sanofi ink €414m IL-17A blocker R&D contract
The company's subsidiary C4X Discovery Ltd got €7m upfront with potential to gain €414m in total for the global commercialisation rights for its...

Germany orders antibody therapies from USA
Although there is no centralised approval required for biologics from the European Medicines Agency, Germany's Health Minister Jens Spahn has...

French biotech investors launch spin-out alliance
Argobio SAS has been kicked off with €50m of committed capital from Kurma Partners, and the state bank Bpifrance. Co-investors include Angelini...